Glaukos Corp GKOS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Glaukos Announces Participation in Upcoming Investor Conferences
Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
Glaukos Announces Third Quarter 2026 Financial Results
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases
Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28
Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
Trading Information
- Previous Close Price
- $244.88
- Day Range
- $239.65–247.12
- 52-Week Range
- $91.84–255.19
- Bid/Ask
- $211.12 / $243.48
- Shares Outstanding
- 59.20M
- Market Cap
- $14.40B
- Volume/Avg
- 712,725 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 20.70
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,094
- Website
- https://www.glaukos.com
Valuation
Metric | GKOS |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 20.20 |
Price/Sales | 20.70 |
Price/Cash Flow | 155.27 |
Price/Earnings
GKOS
Financial Strength
Metric | GKOS |
|---|---|
Quick Ratio | 3.84 |
Current Ratio | 4.57 |
Interest Coverage | −37.25 |
Quick Ratio
GKOS
Profitability
Metric | GKOS |
|---|---|
Return on Assets (Normalized) | −0.70% |
Return on Equity (Normalized) | −0.94% |
Return on Invested Capital (Normalized) | −1.42% |
Return on Assets
GKOS
Medical Devices Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | LOCK|m#&g!r< | LOCK|bBQq | $186B | |||
| Medtronic PLC MDT | LOCK|^W$pKK | LOCK|Hr?# | $132B | |||
| Stryker Corp SYK | LOCK|fzJJ#%Y | LOCK|?>P | $118B | |||
| Boston Scientific Corp BSX | LOCK|&z##T< | LOCK|pPg% | $63B | |||
| Edwards Lifesciences Corp EW | LOCK|b&zf@QYh | LOCK|!@<Y$ | $62B | |||
| GE HealthCare Technologies Inc Common Stock GEHC | LOCK|ds#?!qk | LOCK|Q%t | $38B | |||
| DexCom Inc DXCM | LOCK|mk!<lt%Y | LOCK|p>$W | $30B | |||
| Koninklijke Philips NV ADR PHG | LOCK|%% | LOCK|y?k | $30B | |||
| Steris PLC STE | LOCK|np?B$T | LOCK|dHFym | $25B | |||
| Zimmer Biomet Holdings Inc ZBH | LOCK|Bp%DNdF | LOCK|<M$ | $19B |